{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:12:31Z","timestamp":1781241151573,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C2008207"],"award-info":[{"award-number":["2022R1A2C2008207"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to evaluate the trend of adjuvant chemotherapy (AC) and neoadjuvant chemotherapy (NAC) in patients who underwent radical nephroureterectomy with bladder cuff excision (NUx) for upper tract urothelial carcinoma (UTUC) to compare the perioperative outcomes and overall survival (OS) between AC and NAC using nationwide population-based data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We collected data on patients diagnosed with UTUC and treated with NUx between 2004 and 2016 using the National Health Insurance Service database, and evaluated the overall treatment trends. The AC and NAC groups were propensity score-matched. Cox proportional hazard and Kaplan-Meier analyses were used to assess survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 8,705 enrolled patients, 6,627 underwent NUx only, 94 underwent NAC, and 1,984 underwent AC. The rate of NUx without perioperative chemotherapy increased from 70.8 to 78.2% (R<jats:sup>2<\/jats:sup>\u2009=\u20090.632; p\u2009&lt;\u20090.001). The rates of dialysis (p\u2009=\u20090.398), TUR-BT (p\u2009=\u20091.000), and radiotherapy (p\u2009=\u20090.497) after NUx were similar. In the Kaplan-Meier curve, the NAC and AC groups showed no significant difference (p\u2009=\u20090.480). In multivariate analysis, treatment with AC or NAC was not associated with OS (hazard ratio 0.83, 95% confidence interval 0.49\u20131.40, p\u2009=\u20090.477).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The use of NUx without perioperative chemotherapy has tended to increase in South Korea. Dialysis, TUR-BT, and radiotherapy rates after NUx were similar between the NAC and AC groups. There was no significant difference in OS between the NAC and AC groups. Proper perioperative chemotherapy according to patient and tumor conditions should be determined by obtaining more evidence of UTUC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-022-01112-6","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T09:05:57Z","timestamp":1667984757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Jong Hyun","family":"Tae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Soo","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Hoon","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ho","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Chul","family":"Myung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoungsuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-ki","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Sung","family":"Kyoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"issue":"3","key":"1112_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernandez MI, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35(3):379\u201387.","journal-title":"World J Urol"},{"issue":"4","key":"1112_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.eururo.2008.01.006","volume":"53","author":"R Zigeuner","year":"2008","unstructured":"Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol. 2008;53(4):720\u201331.","journal-title":"Eur Urol"},{"issue":"5","key":"1112_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","volume":"4","author":"C Colla Ruvolo","year":"2021","unstructured":"Colla Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Cucchiara V, Tian Z, Shariat SF, Saad F, Longo N, Montorsi F, et al. Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2021;4(5):792\u2013801.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"1112_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115(6):1224\u201333.","journal-title":"Cancer"},{"issue":"4","key":"1112_CR5","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/j.clgc.2018.01.015","volume":"16","author":"BM Browne","year":"2018","unstructured":"Browne BM, Stensland KD, Moynihan MJ, Canes D. An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database. Clin Genitourin Cancer. 2018;16(4):e743\u201350.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"1112_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.urolonc.2010.07.016","volume":"31","author":"F Audenet","year":"2013","unstructured":"Audenet F, Yates DR, Cussenot O, Roupret M. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol. 2013;31(4):407\u201313.","journal-title":"Urol Oncol"},{"issue":"10232","key":"1112_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268\u201377.","journal-title":"Lancet"},{"key":"1112_CR8","unstructured":"EAU Guidelines. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/."},{"key":"1112_CR9","unstructured":"Korean Statistical Information Service,  (Statistics Korea, Vol. 2022) https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=117&tblId=DT_117N_A00025&conn_path=I2."},{"issue":"11","key":"1112_CR10","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"4","key":"1112_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/JU.0000000000000644","volume":"203","author":"V Margulis","year":"2020","unstructured":"Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, et al. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2020;203(4):690\u20138.","journal-title":"J Urol"},{"issue":"3","key":"1112_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/bju.15389","volume":"128","author":"T van Doeveren","year":"2021","unstructured":"van Doeveren T, van der Mark M, van Leeuwen PJ, Boormans JL, Aben KKH. Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. BJU Int. 2021;128(3):343\u201351.","journal-title":"BJU Int"},{"key":"1112_CR13","unstructured":"Bladder Cancer (version 1.2022)  https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"issue":"11","key":"1112_CR14","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/iju.14068","volume":"26","author":"Y Honda","year":"2019","unstructured":"Honda Y, Nakamura Y, Teishima J, Goto K, Higaki T, Narita K, Akagi M, Terada H, Kaichi Y, Fujii S, et al. Clinical staging of upper urinary tract urothelial carcinoma for T staging: review and pictorial essay. Int J Urol. 2019;26(11):1024\u201332.","journal-title":"Int J Urol"},{"issue":"4","key":"1112_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58(4):581\u20137.","journal-title":"Eur Urol"},{"issue":"5","key":"1112_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","volume":"79","author":"JJ Leow","year":"2021","unstructured":"Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol. 2021;79(5):635\u201354.","journal-title":"Eur Urol"},{"issue":"6","key":"1112_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.clgc.2021.08.005","volume":"19","author":"S Culine","year":"2021","unstructured":"Culine S, Harter V, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, et al. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clin Genitourin Cancer. 2021;19(6):554\u201362.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"1112_CR18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994\u20131007.","journal-title":"Kidney Int"},{"key":"1112_CR19","doi-asserted-by":"publisher","first-page":"967826","DOI":"10.1155\/2014\/967826","volume":"2014","author":"A Ozkok","year":"2014","unstructured":"Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1112_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115\u201324.","journal-title":"Am J Med Sci"},{"key":"1112_CR21","doi-asserted-by":"crossref","unstructured":"Choi SY, Ha MS, Chi BH, Kim JW, Chang IH, Kim TH, Myung SC, Kim M, Lee KE, Kim Y, et al. Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study. J Cancer Res Clin Oncol 2022.","DOI":"10.1007\/s00432-022-03926-1"},{"issue":"5","key":"1112_CR22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.21037\/tau.2016.03.23","volume":"5","author":"T Szarvas","year":"2016","unstructured":"Szarvas T, Modos O, Horvath A, Nyirady P. Why are upper tract urothelial carcinoma two different diseases? Transl Androl Urol. 2016;5(5):636\u201347.","journal-title":"Transl Androl Urol"},{"issue":"6","key":"1112_CR23","doi-asserted-by":"publisher","first-page":"e000126","DOI":"10.1136\/esmoopen-2016-000126","volume":"1","author":"JJ Leow","year":"2016","unstructured":"Leow JJ, Chong KT, Chang SL, Bellmunt J. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open. 2016;1(6):e000126.","journal-title":"ESMO Open"},{"issue":"13","key":"1112_CR24","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","volume":"23","author":"JW Catto","year":"2005","unstructured":"Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23(13):2903\u201310.","journal-title":"J Clin Oncol"},{"key":"1112_CR25","unstructured":"The European Uro-Oncology Group. Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (URANUS). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02969083."}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-022-01112-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T09:06:20Z","timestamp":1667984780000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-022-01112-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1186\/s12894-022-01112-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of the Chung-Ang University Hospital (1908-014-16279). All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of the Chung-Ang University Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Institutional Review Board of the Chung-Ang University Hospital waived the requirement for informed consent because of the retrospective design of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}